MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

50.36 +0.51 (+1.02%)
Streaming Delayed Price Updated: 11:42 AM EDT, Apr 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 219,923
Open 49.51
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 49.85
Today's Range 49.36 - 50.98
52wk Range 34.75 - 60.85
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
The "Liberation Day" Shockwave: US Finalizes 100% Tariffs on Branded Pharmaceutical Imports
In a move that has sent shockwaves through the global healthcare industry, the U.S. Administration officially finalized a sweeping new trade policy on April 6, 2026, imposing 100% tariffs on branded... 
Via MarketMinute
Topics Economy World Trade
News headline image
The Great Metabolic Land Grab: Why Viking and Structure Have Become Big Pharma’s 'Irresistible' Targets
As of April 2026, the biotech landscape has undergone a seismic shift, moving from the "hype cycle" of early weight-loss treatments into an era of aggressive strategic consolidation. The market for... 
Via MarketMinute
Topics Intellectual Property

Performance

YTD
-2.1%
-2.1%
1 Month
-9.1%
-9.1%
3 Month
-2.0%
-2.0%
6 Month
+11.0%
+11.0%
1 Year
+39.9%
+39.9%

More News

Read More
News headline image
Trump Issues Landmark Executive Order: 100% Tariffs on Imported Patented Drugs to Force Onshoring
Via MarketMinute
Topics Economy Government Lawsuit
News headline image
Regeneron Pharmaceuticals: The Scientific Juggernaut Navigating a High-Stakes Transformation
Via Finterra
Topics Economy Intellectual Property World Trade
News headline image
Merck’s Oncology Empire Expands: Keytruda Secures Pivotal European Commission Approval for Recurrent Ovarian Cancer
Via MarketMinute
Topics Intellectual Property
News headline image
The Trillion-Dollar Treatment: A Deep Dive into Eli Lilly and Company (LLY)
Via Finterra
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Biogen Acquires Apellis Pharmaceuticals in $5.6 Billion Deal After Clinical Success
Via MarketMinute
News headline image
United Therapeutics Surges 14% on Groundbreaking Tyvaso Phase 3 Results for IPF
Via MarketMinute
News headline image
The $1 Trillion Goliath: Why Eli Lilly’s $6.3B Centessa Bet Defines the Future of Neuroscience
Via Finterra
Topics Economy Intellectual Property
News headline image
AstraZeneca (AZN) Shares Rally After Breakthrough Chronic Lung Disease Trial Results
Via MarketMinute
Topics Intellectual Property
News headline image
Kodiak Sciences Surges 19% as Phase 3 GLOW2 Trial Delivers Vital Win for Diabetic Retinopathy Treatment
Via MarketMinute
News headline image
Sarepta Therapeutics (SRPT) Stock Surges 34.98% on Breakthrough Clinical Data
Via MarketMinute
News headline image
Merck & Co. (MRK) 2026 Analysis: Navigating the Keytruda Cliff with Pipeline-Driven Resilience
Via Finterra
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Retirees: Collect a High Dividend While Diversifying Your Portfolio With This ETF ↗
Via The Motley Fool
Topics ETFs Retirement
News headline image
Abbott Laboratories Finalizes $21 Billion Acquisition of Exact Sciences, Redefining the Future of Cancer Diagnostics
Via MarketMinute
Topics Supply Chain
News headline image
The Best Healthcare Stocks to Buy With $50 Right Now ↗
Via The Motley Fool
News headline image
Is Eli Lilly's Weight Loss Empire in Trouble? ↗
Via The Motley Fool
News headline image
3 ETFs to Avoid as Oil Shock Hits Markets ↗
Via MarketBeat
Topics ETFs
News headline image
Genentech Provides Update on Phase III persevERA Study in ER-positive Advanced Breast Cancer
From Genentech
Via Business Wire
News headline image
2 Underrated Weight Loss Stocks to Buy Now ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
New England Journal of Medicine Publishes Phase III ALLEGORY Data Showing Genentech’s Gazyva Significantly Reduces Disease Activity in the Most Common Form of Lupus
From Genentech
Via Business Wire
News headline image
Genentech Announces Positive Phase II Results for Petrelintide, an Amylin Analog Developed for People Living With Overweight and Obesity
From Genentech
Via Business Wire
News headline image
Genentech's Fenebrutinib Confirms Its Potential as First and Only BTK Inhibitor for Relapsing and Primary Progressive MS in Third Positive Phase III Study (FENhance 1)
From Genentech
Via Business Wire
News headline image
The Lilly Era: How Eli Lilly Transformed into a Trillion-Dollar Healthcare Titan
Via MarketMinute
Topics Artificial Intelligence ETFs
News headline image
Pfizer Secures Full FDA Approval for BRAFTOVI in First-Line Colorectal Cancer, Bolstering Oncology Growth Strategy
Via MarketMinute
Topics Economy Intellectual Property

Frequently Asked Questions

Is Roche Holding AG Basel American Depositary Shares publicly traded?
Yes, Roche Holding AG Basel American Depositary Shares is publicly traded.
What exchange does Roche Holding AG Basel American Depositary Shares trade on?
Roche Holding AG Basel American Depositary Shares trades on the OTC Traded
What is the ticker symbol for Roche Holding AG Basel American Depositary Shares?
The ticker symbol for Roche Holding AG Basel American Depositary Shares is RHHBY on the OTC Traded
What is the current price of Roche Holding AG Basel American Depositary Shares?
The current price of Roche Holding AG Basel American Depositary Shares is 50.36
When was Roche Holding AG Basel American Depositary Shares last traded?
The last trade of Roche Holding AG Basel American Depositary Shares was at 04/06/26 11:42 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story